PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 234 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type MOST POPULAR Woman Finds Out She Has Breast Cancer From Museum Photo Booth November 1, 2019 GreaterGood Partners with Organization of Hope to Deliver Toys and Necessities... January 5, 2022 Woman Donates 500 Care Packages To Breast Cancer Patients October 11, 2021 Study Suggests Reviewing Lung Cancer Screening Criteria for African Americans July 31, 2019 Load more HOT NEWS Cannabis, cannabinoids and cancer – the evidence so far Teen Gets Bullied After Series Of Drastic Growth Spurts, Now She... ESMO Welcomes European Parliament Resolution Marking World Cancer Day Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer
